Research and Markets: Global Fallopian Tube Cancer Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/nbk95m/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Mentioned - 35 of the 69 Companies Featured

• AbbVie Inc.
• Acceleron Pharma, Inc.
• Adaptimmune Limited
• Amgen Inc.
• Array BioPharma Inc.
• Astex Pharmaceuticals, Inc.
• AstraZeneca Plc
• Bionomics Limited
• Boehringer Ingelheim GmbH
• Caladrius Biosciences, Inc.
• Celsion Corporation
• Cerulean Pharma, Inc.
• Clovis Oncology, Inc.
• Galena Biopharma, Inc.
• Genentech, Inc.
• Genor BioPharma Co., Ltd.
• GlaxoSmithKline Plc
• Glycotope GmbH
• Gradalis Inc.
• Hetero Drugs Limited
• Immune Design Corp.
• ImmunoGen, Inc.
• MabVax Therapeutics Holdings, Inc.
• MedImmune, LLC
• Merck & Co., Inc.
• Merrimack Pharmaceuticals, Inc.
• Millennium Pharmaceuticals, Inc.
• Novartis AG
• Oasmia Pharmaceutical AB
• OBI Pharma, Inc.
• TapImmune Inc.
• Tesaro, Inc.
• TetraLogic Pharmaceuticals
• Vascular Biogenics Ltd.
• VentiRx Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/nbk95m/fallopian_tube.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005385/en/